Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04955938
Title A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Chicago
Indications

essential thrombocythemia

myeloproliferative neoplasm

polycythemia vera

chronic myeloid leukemia

myelofibrosis

myelodysplastic/myeloproliferative neoplasm

Therapies

Enasidenib + Fedratinib

Fedratinib + Ivosidenib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST